El proper dimecres 25 de Febrer, la sala d'actes Pau Viladiu acollirà el seminari “Nanophotonic lab-on-chip biosensors for advanced diagnostics” a càrrec de Laura M. Lechuga, cap del grup de Nanobiosensors i aplicaciones bioanalítiques de l’Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC i CIBER-BBN, Barcelona. Convidada per Marina Rigau (email@example.com)
The dream of having a device in the palm of our hand able to deliver an instant diagnostics of our health status could become a reality soon thanks to the last advances in nanomedicine, nanobiosensors and lab‐on-a‐chip which promise to surpass the existing challenges, opening the door to a global health access. Such point-of-care (POC) diagnostic tools could afford the identification of any disease (as cancer) or any alteration in our cellular pathways at the earliest stage possible in a fast, simple and cost-effective way.
Nanophotonic biosensors (mainly those based on nanoplasmonics and silicon photonics) have revealed themselves as promising candidates for achieving truly POC devices. Advantages as miniaturization, sensitivities clinically relevant, integration capabilities, reliability, and potential for multiplexing can be offered by these nanophotonic technologies. The main objective of our research is to achieve such ultrasensitive platform for POC label-free analysis accomplishing the requirements of disposability and portability. We are employing two types of photonic sensors: nanoplasmonics gold structures and nanophotonic sensors based on novel nanophotonic bimodal interferometric waveguides (patents granted) based on silicon technology that have, as main characteristic, an extreme sensitivity.
Noticeably, we have implemented a first POC laboratory prototype which allows the label-free detection of biomolecular interactions with extreme sensitivity (fM). We have recently demonstrated its ability to directly detect human hormones at physiological levels in human fluids (below 0.1 pg/mL) or microorganisms (at very few cfu/mL) through the immunointeraction with their specific antibodies in body fluids as ascetic liquid. On-going projects include the real-time and fast diagnostics of Malaria, Tuberculosis, colorectal cancer or allergy reactions directly in the patient´s samples.
We are also applying our technology to the analysis of the following gene expression levels: (i) alternative RNA splicing variants; (ii) epigenetics modifications as DNA methylation; (iii) interaction with non-coding RNA regulators such as microRNAs; and (iv) interactions between native surface cell receptors with key molecules, as regulating factors or therapeutic drugs.